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Abstract
Aim: Altered vitamin D signaling is associated with cardiac dysfunction, but the pathogenic mechanism is not clearly
understood. We examine the mechanism and the role of vitamin D signaling in the development of cardiac dysfunction.
Methods and Results: We analyzed 1a-hydroxylase (1a-OHase) knockout (1a-OHase
2/2) mice, which lack 1a-OH enzymes
that convert the inactive form to hormonally active form of vitamin D. 1a-OHase
2/2 mice showed modest cardiac
hypertrophy at baseline. Induction of pressure overload by transverse aortic constriction (TAC) demonstrated exaggerated
cardiac dysfunction in 1a-OHase
2/2 mice compared to their WT littermates with a significant increase in fibrosis and
expression of inflammatory cytokines. Analysis of calcium (Ca
2+) transient demonstrated profound Ca
2+ handling
abnormalities in 1a-OHase
2/2 mouse cardiomyocytes (CMs), and treatment with paricalcitol (PC), an activated vitamin D3
analog, significantly attenuated defective Ca
2+ handling in 1a-OHase
2/2 CMs. We further delineated the effect of vitamin D
deficiency condition to TAC by first correcting the vitamin D deficiency in 1a-OHase
2/2 mice, followed then by either a daily
maintenance dose of vitamin D or vehicle (to achieve vitamin D deficiency) at the time of sham or TAC. In mice treated with
vitamin D, there was a significant attenuation of TAC-induced cardiac hypertrophy, interstitial fibrosis, inflammatory
markers, Ca
2+ handling abnormalities and cardiac function compared to the vehicle treated animals.
Conclusions: Our results provide insight into the mechanism of cardiac dysfunction, which is associated with severely
defective Ca
2+ handling and defective vitamin D signaling in 1a-OHase
2/2 mice.
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Introduction
Cardiovascular disease (CVD) is the most common cause of
mortality and morbidity in the United States and other developed
nations. Clinical and epidemiological studies suggest an association
between vitamin D deficiency and various cardiovascular disorders
[1,2], and vitamin D therapy has been shown to improve
cardiovascular function [3]. Particularly, in patients with chronic
renal failure (CRF), vitamin D deficiency is uniformly present
because the critical conversion of nutritional vitamin D3
(25(OH)D3) to the hormonally active form of vitamin D3
(1,25(OH)2D3) occurs primarily in the kidney by 1a-hydroxylase
(1a-OHase)[4]. CRF has been shown to be an independent risk
factor for CVD, with 10–20 times greater incidence of cardiovas-
cular disease in CRF patients [5]. Clinical studies have also
demonstrated that there is an association between improved
survival and decreased cardiovascular mortality in hemodialysis
patients treated with an activated vitamin D analog, paricalcitol
(PC) [6,7]. In fact, similar to CRF patients, 1a-OHase knockout
(1a-OHase
2/2) mice show baseline hypertension, cardiac hyper-
trophy, and impaired cardiac function [8]. Despite these
associations between vitamin D deficiency and cardiac dysfunc-
tion, the pathogenic mechanism of cardiac dysfunction associated
with vitamin D deficiency is not fully elucidated.
Cardiomyocyte (CM) contractility is regulated by Ca
2+ handling
contractile proteins via regulation of intracellular levels of Ca
2+
[9]. Thus, abnormalities in Ca
2+ homeostasis, as seen in vitamin D
deficiency, may lead to a chronic defect in E–C coupling, which
may in turn lead to cardiac dysfunction. Delays in Ca
2+ transients,
for example, have been observed in myocardial tissue obtained
from failing hearts [10]. Although it might not be surprising to find
abnormal Ca
2+ handling in a vitamin D deficiency state, the exact
mechanism of vitamin D deficiency affecting the Ca
2+ handling in
CMs, however, is poorly understood. In this study, we examined
whether abnormal Ca
2+ homeostasis and Ca
2+ handling may
mediate structural and functional cardiac abnormalities and
examined the relationship between vitamin D deficiency and the
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e108382development of cardiac hypertrophy in 1a-OHase
2/2 mice. We
hypothesize that restoration of vitamin D signaling improves




Experiments were conducted using 8–10-week old male 1a-
OH
2/2 mice and their littermates in a C57BL/6 background. 1a-
OHase
+/2 and 1a-OHase
2/2 mice were produced from 1a-
OHase
+/2 [11]. All mice, breeders and offspring were housed at
the Animal Research Facility at Beth Israel Deaconess Medical
Center (BIDMC) under pathogen-free conditions with a reverse
daily 12:12 h light: dark cycle. Euthanasia was performed by CO2
via a gas cylinder. All experimental procedures were approved by
the Institutional Animal Care and Use Committee of BIDMC.
Animal surgery and hemodynamic measurement
TAC was performed in 8–10 week old male C57BL/6 mice and
in 1a-OHase
2/2 [12,13] mice. Cardiac function was analyzed
using echocardiography (for baseline cardiac function) and left
ventricular (LV) pressure-volume loop measurement (after TAC)
as described previously [14,15]. Detailed method is provided in
Text S1.
Morphometric analysis of isolated CMs
CMs were enzymatically dissociated from 12 weeks old male
mouse hearts according to previously described protocol [16,17].
Detailed method is provided in Text S1.
Serum Ca
2+ and vitamin D metabolite analysis
Serum 1, 25(OH)2 D3 (n=8–10 replicates per group) was
analyzed via enzyme immunoassays using commercial kits
(Immunodiagnostic Systems). Serum Ca
2+ (n=8–10) was analyzed
via a quantitative Calcium Colorimetric Detection Kit (Bio
Vision).
Serum PTH analysis
Serum PTH (n=8–10 replicates per group) was analyzed via
enzyme immunoassays using commercial kits (Immunooptics Inc.)
Ca
2+ transients and cell shortening measurements of
isolated CMs
Measurement of Ca
2+ transient and cell shortening in isolated
CMs [18]. Briefly, CMs were isolated and contraction parameters
and Ca
2+ transient [Ca
2+] i were measured in response to electrical
stimulation. Caffeine induced [Ca
2+] i release was measured after
a 10-second pause following steady-state stimulation at increasing
rates. Detailed methods are described in Text S1.
Histology and Western Blots
Hearts were fixed in 10% formalin and paraffin-embedded.
Sections were stained with hematoxylin and eosin and Masson
Trichrome (MT) at the Histology Core facility at BIDMC [14,15].
Quantification of fibrosis was performed as described previously
[16]. To compare the levels of the major proteins involved in Ca
2+
handling, Western blot analysis was performed on total protein
from WT and 1a-OHase
2/2 mice as described previously [14,15].
Statistical Analysis
Data are reported as mean SEM. Statistical significance was
determined by one-way or two-way ANOVA and Student-
Newman-Keuls post hoc test. Values of p,0.05 were considered
significant.
Results
Exaggerated hypertrophic responses after transverse
aortic constriction (TAC) in 1a-OHase
2/2 mice
At baseline, 1a-OHase
2/2 mice demonstrated a modest 5%
increase in heart weight compared to their WT littermates at 12
weeks of age (Fig. 1A). Corresponding isolated adult CMs also
demonstrated modest increase in surface areas of 1a-OHase
2/2
mice compared to the age and gender matched WT mice (Fig. 1B
and 1C). Cross sectional area of the CMs further confirmed these
findings (Fig. 1D and 1E). We also observed that baseline systolic
cardiac function was modestly reduced in 1a-OHase
2/2 mice
compared with the WT mice (Fig. 1F). In addition, the mean
arterial pressure (MAP) of 1a-OHase
2/2 was significantly higher
than that of WT littermate mice (Fig. 1G). These findings
suggested that there is baseline mild cardiac hypertrophy and
cardiac dysfunction in 1a-OHase
2/2 mice compared to the WT
mice.
To elucidate the effect of defective vitamin D signaling under
pathological conditions, we imposed pressure overload on the
heart using TAC. Morphometric analysis demonstrated significant
increases in heart weight/body weight (HW/BW) ratio in both 1a-
OHase
2/2 and WT mice compared with the corresponding
sham-operated groups after 4 weeks of TAC (Fig. 2A and 2B).
However, there were exaggerated hypertrophic responses to TAC
in 1a-OHase
2/2 mice heart compared to the WT mice. Cardiac
functional analysis using pressure-volume (PV) loop measurement
revealed that 1a-OHase
2/2 mice demonstrated significantly
greater cardiac dysfunction after TAC, as observed by reduction
in stroke volume and cardiac output, compared to their WT
littermates (Fig. 2C and 2D).
We further analyzed these hearts for the presence of interstitial
fibrosis using Masson-Trichrome staining We found that both WT
and 1a-OHase
2/2 mice showed presence of fibrosis after TAC,
(Fig. 2E) which was significantly increased in 1a-OHase
2/2 mice
compared with those in WT mice (WT =11.961.5% vs. 1a-
OHase
2/2 =21.561.2%; p,0.05). These findings demonstrated
that there were exaggerated pathological responses to TAC in 1a-
OHase
2/2 mice that are associated with greater decreased cardiac
function and more aggressive development of cardiac fibrosis.
Increased fetal gene activation and inflammatory
responses after TAC in 1a-OHase
2/2 mice
We determined the biochemical markers for cardiac hypertro-
phy and heart failure by measuring the level of ‘‘fetal’’ genes, such
as atrial natriuretic factor (ANF) and brain natriuretic peptide
(BNP). Ventricular ANF was significantly expressed in all TAC
groups. However, there was a 8-fold greater increase in ANF
mRNA levels after TAC in 1a-OHase
2/2 mice compared to the
WT littermates (Fig. 3A). Similarly, there was also a greater
increase in BNP expression in 1a-OHase
2/2 mice compared to
the WT mice hearts after TAC (Fig. 3B). Another marker for
cardiac hypertrophy, the ratio of ß-MHC to total MHC mRNA
expression, was also increased after TAC in both groups. Yet,
there were again dramatic and exaggerated increases observed in
1a-OHase
2/2 mice compared to the WT mice after TAC
(Fig. 3C).
It’s known that vitamin D, a steroid hormone, affects immune
regulation by preventing excessive expression of inflammatory
cytokines and increasing the ‘oxidative burst’ potential of
macrophages [19]. Interestingly, we observed a reduction in
Abnormal Calcium Handling and Exaggerated Cardiac Dysfunction
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e108382Figure 1. Physiological, echocardiographic, and hemodynamic parameters in 1aOHase2/2 mice at baseline: (A) Baseline HW/BW of
1a-OHase 2/2 mice. *, p,0.05 compared to WT. N=8–10. (B and C) Isolated adult CMs from 1a-OHase
2/2 mice showing increased surface area
compared to WT CMs. *, p,0.05 compared to WT. N=8–10. (D) Cross sectional area of mice heart showing CM surface area. (E) Resting sarcomere
length of 1a-OHase
2/2 and WT CMs. *, p,0.05 compared to WT. N=8–10. (F) Baseline fractional shortening (FS) of WT and KO mice. *, p,0.05
compared to WT. N=8–10. (G) MAP of WT and 1a-OHase2/2 mice at baseline. *, p,0.05 compared to WT. N=8–10.
doi:10.1371/journal.pone.0108382.g001
Figure 2. In response to pressure overload mutant mice showing exaggerated hypertrophy. (A) Representative hearts after 4 weeks
of sham or TAC in WT and 1a-OHase
2/2 mice. (B) HW/BW after 4 weeks of sham or TAC in WT and 1a-OHase
2/2 mice. *, p,0.05 compared to WT.
#, p,0.05 compared to sham. {, p,0.05 compared to WT TAC. N=8–10. (C and D) Stroke volume (C) and cardiac output (D) in WT and 1a-OHase
2/2
mice after 4 weeks of sham or TAC. *, p,0.05 compared to WT. #, p,0.05 compared to sham. {, p,0.05 compared to WT TAC. N=8–10.
(E) Representative Masson-Trichrome heart staining in 1a-OHase
2/2 mice after 4 weeks of sham or TAC.
doi:10.1371/journal.pone.0108382.g002
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OHase
2/2 mice compared to WT mice. Although no significant
differences were observed in TNF-a expression after TAC in WT
mice, 1a-OHase
2/2 mice hearts showed enhanced activation of
TNF-a after TAC (Fig. 3D). Another inflammatory marker,
monocyte chemotactic protein-1 (MCP-1), was activated by TAC
in both mice, but with significantly greater activation was observed
in 1a-OHase
2/2 mice after TAC (Fig. 3E). These findings
demonstrated that there is an exaggerated biochemical evidence of
cardiac dysfunction and uncontrolled immune response associated
with TAC in 1a-OHase
2/2 mice.
Defective Ca
2+ handling and modulation of Ca
2+
regulatory protein expressions in 1a-OHase
2/2 mice CMs
We found that the circulating 1, 25(OH) vitamin D3 level was
undetectable in 1a-OHase
2/2 mice and significantly reduced in
heterozygous 1a-OHase
+/2 littermates (Fig. 4A), which coincide
with previous findings [20,21]. Without vitamin D supplementa-
tion, 1a-OHase
2/2 mice at 12 weeks showed severe hypocalcemia
with plasma Ca
2+ concentrations as low as 1.2 mmol/Lincontrastto
the WT littermates, which exhibited normal plasma Ca
2+ concen-
trations (WT=2.5 mmol/L vs. 1a-OHase
2/2 =1.2mmol/L;
P,0.05). Supplementation of vitamin D using injection of PC
(200 ng/kg), an activated vitamin D3 analog, starting at 4 weeks after
birth normalized the plasma Ca
2+ concentration in 1a-OHase mice
by 12 weeks (Fig. 4B).
To examine the effect of the vitamin D deficiency in CMs,
contraction parameters of individual isolated CM from 1a-
OHase
2/2 mice and their WT littermates were studied by
measuring sarcomere shortening (contraction) and relengthening
(relaxation) in response to electrical stimulation (see Text S1 for
detail). Baseline 1a-OHase
2/2 CM sarcomeres were significantly
larger compared to WT (Fig. 4C, Table S1). Additionally, 1a-
OHase
2/2 CMs showed a significant decrease in peak shortening,
as well as the rate of cell shortening and rate of cell relengthening
compared to WT CMs (Fig. 4D and 4E). Peak shortening is
calculated from the percent shortening of length data (Fig. 4D).
The highest and lowest value reached by the transient.
We then investigated Ca
2+ handling properties of individual
CM from 1a-OHase
2/2 mice (see Text S1 for detail). Analysis
of Ca
2+ transients indicated decreased peak systolic Ca
2+,
measured as Fura-2 ratios in CM from 1a-OHase
2/2 compared
to WT group CM (Fig. 4F). The rate of Ca
2+ transient decay (tau,
exponential decay of time constant, the speed of relaxation/
calcium uptake) was also significantly reduced in 1a-OHase
2/2
CMs (Fig. 4G) which was calculated by the ionoptix program
from the transient, with a reduced time to peak (TTP) and a
decrease in relaxation rate (Ca
2+ efflux) (Fig. 4H and 4I).
Caffeine causes Ca
2+ release from the sarcoplasmic reticulum (SR)
of mammalian muscle. Thus, to evaluate the SR Ca
2+ load, we
tested caffeine-induced Ca
2+ release amount from SR in WT and
1a-OHase
2/2 CMs. We found that CMs from 1a-OHase
2/2
mice presented a decreased caffeine-induced Ca
2+ transient
compared to WT CMs (Fig. 4J). These findings demonstrated
profound Ca
2+ handling abnormalities in 1a-OHase
2/2 mice
CMs, which may contribute to the development of fulminant heart
failure after TAC.
The expression level and the activity of sarcoplasmic reticulum
Ca
2+ ATPase (SERCA) is significantly decreased in pressure
overload-induced hypertrophy and during heart failure in animals
and human, which correlate with decreased myocardial dysfunc-
tion [22,23]. To further elucidate the mechanism underlying the
defective Ca
2+ handling, we examined the SERCA2a protein
expression level in these mice. We found that 1a-OHase
2/2 mice
showed significant decreased SERCA2a expression after TAC
compared to WT mice (Fig. 5A and 5B). Phospholamban (PLB)
interacts with SERCA and inhibits its Ca
2+ transport rate, and the
relative abundance of SERCA and PLB maintains Ca
2+ homeo-
stasis and CM contractility. Therefore, SERCA/PLB ratio reflects
Ca
2+ transport capacity of the SR [24]. At baseline, 1a-OHase
2/2
Figure 3. Biochemical findings after 4 weeks of Pressure overload in 1aOHase
2/2 mice. (A–C) Real-time PCR mRNA expression of ANF (A),
BNP (B) and of ß-MHC to total MHC ratio (C) in WT and 1a-OHase
2/2 mice after 4 weeks of sham or TAC. *, p,0.05 compared to WT. #, p,0.05
compared to sham. {, p,0.05 compared to WT TAC. N=8–10. (D and E) Real-time PCR mRNA expression of inflammatory cytokines TNF-a (D) and
MCP-1 (E) in WT and 1a-OHase -/- mice after 4 weeks of sham or TAC. *, p,0.05 compared to WT. #, p,0.05 compared to sham. {, p,0.05 compared
to WT TAC. N=8–10.
doi:10.1371/journal.pone.0108382.g003
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after TAC (Fig. 5A and 5B). SERCA/PLB ratio was also
significantly decreased in 1a-OHase
2/2 mice compared to WT
mice (Fig. 5C). This may explain the difference in SR Ca
2+ load
and contractile function between WT and 1a-OHase
2/2 mice
CMs, and the depressed levels of SERCA2a may contribute to the




2+-exchanger (NCX) is the dominant myocardial
Ca
2+ efflux mechanism. Ca
2+ removal from the cytosol occurs by
activity of the SR Ca
2+ pump and by exchange of Ca
2+ for sodium
by the sarcolemmal NCX [25]. The decrease in PLB might lead to
a higher activation of the remaining SERCA pumps and increase
the activity of NCX [26]. At baseline, there were no significant
difference in expression of NCX between the WT and 1a-
OHase
2/2 mice (Fig. 5A and 5B). However, we found
significant up-regulation of NCX expression in banded WT and
1a-OHase
2/2 mice with significant 4-folds increase seen in 1a-
OHase
2/2 mice. A relative increase in NCX is expected when SR
function is impaired [27]. The function of ryanodine receptor 2
(RyR2) (the cardiac isoform) is to allow Ca
2+-induced Ca
2+ release
that brings about contraction, while myocyte relaxation results in
RyR2 closure accompanied by the Ca
2+ re-uptake into SR
through the SERCA [28]. After TAC, there was a moderate
decrease in RyR2 expression in both WT and 1a-OHase
2/2 mice
(Fig. 5A and 5B).
Treatment with PC attenuates cardiac dysfunction after
TAC in 1a-OHase -/- mice
The responses of 1a-OHase
2/2 mice to TAC in our previous
experiments may be compounded by their baseline cardiac
hypertrophy. Thus, we further determined the specific role of
defective vitamin D to pathological conditions by first using
‘‘rescue’’ vitamin D protocol as described previously in 1a-
OHase
2/2 mice, where vitamin D deficiency and its non-cardiac
phenotype were both corrected [29]. From 28–30 days of life, 1-a-
OHase
2/2 mice were treated with an initial ‘‘rescue’’ dose of
500 ng/kg of PC, followed by a daily ‘‘maintenance’’ dose of
200 ng/kg from 5 to 8 weeks of age. At 8 weeks, the animals were
Figure 4. Contractile function and Ca
2+ transient parameters in isolated CMs from 1aOHase 2/2 mice. (A and B) Baseline 1, 25(OH)2D3
(A) and free Ca
2+ (B) level in WT and 1aOHase 2/2 mice serums. *, p,0.05 compared to WT, N=6–8 mice. (C) Resting cell length (D) and peak
shortening (% of cell length) from isolated CMs obtained from WT and 1aOHase 2/2 mice. *, p,0.05 compared to WT. Ten twitches per CMs were
collected for each mouse heart. N=6–8 mice/group. (E) Continuous measurement of cell contractility from isolated CMs obtained from WT (blue line)
and 1aOHase
2/2 (red line) mice. *, p,0.05 compared to WT. Ten twitches per CMs were collected for each mouse heart. N=6–8 mice/group. (F)
Representative Fura 2 ratio (F340/380) from isolated CMs obtained from WT (blue line) and 1aOHase -/- (red line) mice. Data shows that the twitch
peak amplitudes are significantly different between WT and 1aOHase -/- CMs, which indicate severely defective Ca
2+ handling in 1aOHase
2/2 CMs.
(G–I) The rate of Ca
2+ transient decay (Tau) (G), time to peak contraction (TTP) (H), and return velocity to baseline or Ca
2+ efflux in WT and 1aOHase
2/2
CMs. *, p,0.05 compared to WT. N=10 CMs/mouse heart. N=6–8 mice/group. (J) Representative traces of Ca
2+ transients evoked by 10 mM caffeine
recorded in WT (blue line) and 1aOHase
2/2 (red line) mice CMs.
doi:10.1371/journal.pone.0108382.g004
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TAC, 3) PC + Sham, and 4) PC+TAC. For the vehicle conditions,
maintenance doses of PC were changed to vehicle injections, while
the PC dose was maintained for PC groups. TAC resulted in a
significant increase in HW/BW and LW/BW ratios in mice
receiving vehicle for 4 weeks compared to the sham operated mice
(Fig. 6A and 6B). In mice treated with PC, there was a significant
18% attenuation of TAC-induced HW/BW ratio increase
compared to the vehicle treated animals. Histological examination
demonstrated that interstitial fibrosis induced by TAC in vehicle-
administered 1a-OHase
2/2 mice were significantly inhibited in
PC treated group after TAC (Fig. 6C). TAC-induced increases in
ANF and b-MHC gene expression, which were both attenuated by
PC treatment (Fig. 6D and 6E).
We found that decreased fractional shortening after TAC in
vehicle treated mice was significantly improved with vitamin D
replacement in 1a-OHase
2/2 mice (Fig. 6G). In addition, we
observed reduced stroke volume and cardiac output in vehicle
treated group after TAC. These parameters also improved after
vitamin D replacement (Fig. 6G and 6H). Thus, vitamin D
replacement resulted in significant attenuation of cardiac dysfunc-
tion after TAC in 1a-OHase
2/2 mice.
Treatment with PC attenuates defective Ca
2+ handling
associated with defective vitamin D signaling
To further assess the effect of vitamin D replacement on CMs
contractility in 1a-OHase
2/2 mice contraction parameters, we
performed Ca
2+ handling analysis of isolated CMs in1a-OHase
2/2
mice with or without PC treatment. We found that vitamin D
replacement attenuated hypocontractility and increased peak
shortening in PC treated 1a-OHase
2/2 mice (Fig. 6I and 6J).
Rate of relaxation was significantly increased with PC treatment
and the rate of Ca
2+ transient decay (tau) was significantly improved
(Fig. 6K and 6L). Treatment with PC also normalized the PTH
level in1a-OHase
2/2 mice (Fig. 7). Thesefindings suggest that the
pathological response in 1a-OHase
2/2 mice is mainly due to
defective vitamin D signaling and associated Ca
2+ handling, and
correcting these abnormalities could rescue these pathological
responses.
Discussion
In this study, we demonstrated that vitamin D deficiency is
associated with cardiac hypertrophy at baseline results in an
exaggerated progression to heart failure after pressure overload in
1a-OHase
2/2 mice. We also found that there is defective Ca
2+
handling in 1a-OHase
2/2 mice, with structural and functional
cardiac abnormalities in these mice. These cardiac Ca
2+ handling
abnormalities were completely corrected with vitamin D replace-
ment in 1a-OHase
2/2 mice. Thus, our studies strongly support
the notion that vitamin D deficiency is an under-recognized, non-
classic risk factor for developing heart failure that is readily
correctable.
Vitamin D is known for its primary role in Ca
2+ and bone
homeostasis [30]. Biological activities of vitamin D are mediated
by a hormonally active 1, 25-dihydroxyvitamin D3 that is
converted from 25-hydroxyvitamin D3 by 1a-OHase. It binds to
Figure 5. Expressions of Ca
2+ regulatory protein in mice with altered metabolism of Vitamin D. (A) Representative western blots of
various Ca
2+ handling proteins. (B) Quantitative analysis of various Ca
2+ handling proteins. NCX =Na
+/Ca
2+ exchanger, SERCA2a = sarcoplasmic
reticulum Ca
2+ ATPase, PLB = phospholamban, and RYR = ryanodine receptor. GAPDH = glyceraldehyde 3-phosphate dehydrogenase. GAPDH was
used as internal loading control. *, p,0.05 compared to WT. #, p,0.05 compared to sham. {, p,0.05 compared to WT TAC. N=8–10. (C) Quantitative
analysis of SERCA/PLB protein expression ratio. *, p,0.05 compared to WT. #,p ,0.05 compared to sham, N=8–10.
doi:10.1371/journal.pone.0108382.g005
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PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e108382Figure 6. Effect of paricalcitol on cardiac dysfunction parameters. (A) Representative hearts in 1a-OHase
2/2 mice with or without PC
treatment after 4 weeks of sham or TAC. (B) HW/BW ratio in 1a-OHase
2/2 mice with or without PC treatment after 4 weeks of sham or TAC. *, p,0.05
compared to Sham. #, p,0.05 compared to vehicle TAC. N=8–10. (C) Representative Masson-Trichrome heart staining in 1a-OHase
2/2 mice with or
without PC treatment after 4 weeks of sham or TAC. (D and E) Real-time PCR mRNA expression of ANF (D) and of ß-MHC to total MHC ratio (E) after 4
weeks of sham or TAC in 1a-OHase
2/2 mice with or without PC treatment. *, p,0.05 compared to Sham. #, p,0.05 compared to vehicle TAC. N=8–
10. (F–H) Fractional shortening (F), stroke volume (G) and cardiac output (H) in 1a-OHase -/- mice with or without PC treatment after 4 weeks of sham
or TAC. *, p,0.05 compared to Sham. #, p,0.05 compared to vehicle TAC. N=8–10. Effect of paricalcitol on defective calcium handling in 1aOHase
2/2 mice. (I–L). The % peak Ca
2+ (I), % peak shortening (J), the rate of Ca
2+ transient decay (Tau) (K), and the return velocity to baseline or Ca
2+ efflux
(L) in 1a-OHase
2/2 mice with or without PC treatment. *, p,0.05 compared to vehicle treated mice group, N=20 CMs/mouse from 6–8 mice/group.
doi:10.1371/journal.pone.0108382.g006
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superfamily of nuclear receptors for steroid hormones [4]. Vitamin
D plays an important physiological role in controlling cardiac
functions and vitamin D-dependent signaling systems are present
in cardiac myocytes and fibroblasts [31]. Vitamin D deficiency has
been associated with abnormal cardiac relaxation, proliferation,
and increased cardiac renin gene expression [32,33]. Previously,
we showed that vitamin D therapy prevents the progression to
cardiac hypertrophy [34], and attenuates the development of heart
failure in salt sensitive rat model [35]. In addition, 1a-OHase -/-
mice developed hypertension, cardiac hypertrophy, and impaired
cardiac systolic function, possibly due to the activation of the RAS
[8]. Clinically, vitamin D deficiency has been associated with the
increased prevalence of myocardial dysfunctions and heart failure
[36,37]. Since the critical conversion of the storage form to the
active form of vitamin D by 1a-OHase occurs in the kidney,
patients with CKD are typically vitamin D deficient. In fact, the
prevalence of cardiac hypertrophy and cardiac dysfunction is over
80% in these patients [38,39], and vitamin D therapy has been
shown to improve survival and decrease cardiovascular mortality
[6,7]. These findings suggest that the role of vitamin D signaling
may be significant in the heart, and vitamin D deficiency may offer
novel therapeutic target in the treatment of heart failure.
CM contraction is regulated by the interplay between Ca
2+,
contractile proteins, and the intracellular handling of Ca
2+,
whereas abnormal Ca
2+ homeostasis is primarily responsible for
depression of CM contractility [22,23]. In several animal and
human models of cardiac hypertrophy and heart failure, the
whole-cell [Ca
2+]i transient is altered [40,41]. Decreases in
SERCA pump expression and activity have been observed in a
variety of animal and human models of heart failure and a degree
of decrease in SERCA level and its activity, closely correlate with a
decreased myocardial function [27]. Thus, these data suggest that
alterations in Ca
2+ handling proteins are important contributors to
cardiac dysfunction and heart failure. We found profound Ca
2+
transient abnormalities, contractile abnormalities and altered
expression of various Ca
2+ handling regulatory proteins in vitamin
D deficient CMs, which became exaggerated after TAC.
Abnormalities in Ca
2+ homeostasis, as seen in vitamin D
deficiency, may lead to a chronic defect in E–C coupling, which
may in turn lead to cardiac dysfunction. Particularly, decreased
SERCA and SERCA/PLB expression in 1a-OHase
2/2 mice
supports the hypothesis that alterations in abundance or activity of
molecules that regulate systolic and diastolic Ca
2+ are centrally
involved in depressed contractility in hypertrophied and failing
hearts.
The key role of cardiac hypertrophy in the pathogenesis of heart
disease underscores the need to identify the cellular and molecular
mechanisms responsible for both cardiac hypertrophy and its
progression to heart failure. A better understanding of disease
progression may facilitate the development of novel therapeutic
modalities, as well as the development of better guidelines for the
prevention of cardiac hypertrophy. Our findings contribute to a
better understanding of disease progression that are involved in
vitamin D signaling and the development of heart failure. Our
finding provides evidences that Ca
2+ homeostasis and Ca
2+
handling mediate structural and functional cardiac abnormalities
in vitamin D deficient 1a-OHase
2/2 mice and development of
cardiac hypertrophy.
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